Adenocarcinoma Management at the Esophagogastric Junction

Adenocarcinoma of the esophagogastric junction—tumours arising at the anatomical interface between the distal oesophagus and proximal stomach—has shown a steady global increase, driven in part by obesity, gastro-oesophageal reflux and Barrett’s oesophagus. Classification by Siewert type guides both staging and surgical approach, determining whether oesophagectomy, gastrectomy or a hybrid resection optimises margins and lymphadenectomy. Early lesions confined to the mucosa may be managed by endoscopic resection techniques, while locally advanced tumours benefit from multimodal regimens combining neoadjuvant chemotherapy or chemoradiotherapy with surgical resection. Advances in minimally invasive and robotic surgery have reduced perioperative morbidity, and the advent of molecular markers is beginning to inform adjuvant and targeted therapies. Despite these gains, long-term survival remains limited by nodal metastases and distant spread, underscoring the need for personalised risk stratification and refinements in systemic treatments.

Research from Nature Portfolio

Recent studies have demonstrated the utility of a nomogram integrating patient age, tumour stage, histological grade and lymphovascular invasion to predict the likelihood of liver metastases at initial presentation. This tool exhibited strong discriminative performance (c-index > 0.80) and robust calibration in internal validation, enabling clinicians to identify high-risk individuals for intensified imaging surveillance or early systemic therapy. The study emphasises the emerging role of quantitative prognostic models in tailoring management plans and may inform decision-making for adjuvant treatment in those with elevated metastatic potential.

Adenocarcinoma Management at the Esophagogastric Junction publication trend

The graph below shows the total number of articles in adenocarcinoma management at the esophagogastric junction across all publications each year (not limited to Nature Index journals).

Technical terms

Adenocarcinoma: A malignant epithelial tumour originating from glandular tissue.
Esophagogastric junction (EGJ): The anatomical region where the distal oesophagus meets the proximal stomach.
Neoadjuvant therapy: Systemic or radiation treatment administered before surgical resection to down-stage the tumour.
Siewert classification: A scheme dividing EGJ adenocarcinomas into three types based on the tumour’s epicentre relative to the gastric cardia.
Nomogram: A graphical predictive model that combines multiple prognostic factors to estimate the probability of a clinical event.

References

1. Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023. Gastric Cancer (2024).
2. The Multidisciplinary Approach and Surgical Management of GE Junction Adenocarcinoma. Cancers (2024).
3. Nomogram for predicting the likelihood of liver metastases at initial diagnosis in patients with Siewert type II gastroesophageal junction adenocarcinoma. Scientific Reports (2023).
4. Age-dependent benefit of neoadjuvant treatment in adenocarcinoma of the esophagus and gastroesophageal junction: a multicenter retrospective observational study of young versus old patients. International Journal of Surgery (2023).